Status: Recruiting
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Participants needed: 200
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Chulalongkorn UniversityUpdated: Jun 16, 2026Locations: 1
Eligibility criteria
Age 18 years or more [+3]
Denied to participate in the study [+13]